The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
PHASE2CompletedINTERVENTIONAL
Enrollment
72
Participants
Timeline
Start Date
May 31, 1998
Primary Completion Date
March 31, 2000
Conditions
HIV Infections
Interventions
DRUG
Aldesleukin
Trial Locations (1)
77030
Thomas Street Clinic C605-020 CRS, Houston
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000825 - The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 | Biotech Hunter | Biotech Hunter